The trust crisis of traditional Chinese medicine caused by many kinds of traditional Chinese medicine being questioned and not evaluated

2013-05-24 source: Recently, many traditional Chinese medicine enterprises have made great waves in the international and domestic society due to the use of toxic pieces or some poisonous herbs The reporter of "economic reference" interviewed many domestic authoritative experts, who pointed out that the carcinogens in drugs are not all banned, which is the consensus of traditional Chinese medicine and Western medicine After formal and scientific processing methods and means, these herbs can be used as medicine safely, but the key is that enterprises need to continuously research and re evaluate the drugs A variety of traditional Chinese medicine ingredients have been questioned recently Tongrentang products, a century old shop, have been in constant trouble First, the Hong Kong Health Department issued a notice that a group of Tongrentang's "five tonic pills" were found to have excessive mercury (mercury) content Recently, it was exposed that the cinnabar content of Niuhuang Qianjin powder and Xiaoer Zhibao pill, two other products of Tongrentang, were 17.3% and 0.72% respectively The former is beyond the domestic standard, and the latter is far beyond the Hong Kong standard Tongrentang has not made any official response so far Chinese patent medicine is not only the product of Tongrentang, but also the product of Tongrentang, because of its toxic ingredients or the view of Western medicine Before this incident, Zhengtian pill, a traditional Chinese medicine for treating migraine produced by China Resources Sanjiu group, was considered to be toxic in the UK because it contained Aconitum herb, which was once regarded as the "king of poison" by ancient Greeks, and may be toxic to heart or nervous system As a result, this ingredient has been included in the list of strictly restricted herbs in the UK The British medicines and health products watchdog (MHRA) said it had found a herbalist providing patients with the untested migraine pill, saying it had received three reports of side effects in the past One patient had kidney problems after taking the medicine, another had dizziness and abnormal sensation, and the third patient had palpitation, pain and shortness of breath After stopping taking the medicine, the body returned to normal There are carcinogens are not all banned according to the provisions of the Pharmacopoeia of China Mercury and aconite are toxic pieces of decoction, which can only be used as medicine after being processed and detoxified Experts believe that there are misunderstandings about the use of some traditional Chinese medicine at home and abroad, which greatly affects the promotion of traditional Chinese medicine in the world "Now there is a wrong concept, that there are toxic and harmful substances in traditional Chinese medicine, and carcinogens should be banned This concept is wrong." Li Lianda, academician of the Chinese Academy of engineering, pointed out that hundreds of Western medicines contain carcinogens, and some anticancer drugs can fight cancer on the one hand, on the other hand, they have carcinogens themselves, and can also cause cancer There are dozens of Western medicines that can cause cancer, but they are now used clinically He thinks that if according to the view of some people, as long as there are carcinogens in drugs, they should be banned, and there are at least hundreds of Western drugs should be banned, then what should we use clinically? What does it take to cure the disease and save people? Chinese medicine is also, now the Chinese medicine mentions that there are ten kinds and eight kinds of suspicious carcinogens, not only areca, are these western medicine and Chinese medicine all forbidden to use? But in fact, it is widely used in clinic Western medicine has been sure to have carcinogenic drugs still used as usual, Chinese medicine also has this situation Clinical practice is not to ban all, but to weigh the advantages and disadvantages Beijing University of Chinese Medicine professor Ji Shaoliang said that a survey showed that the long-term chewing areca and oral cancer incidence rate is related, and the areca has so far no clinical reports can cause cancer, and no reliable evidence that areca is carcinogenic substances For the fundamental difference between "chewing betel nut" and "using betel nut as medicine", Ji Shaoliang thinks that the betel nut used in "chewing betel nut" is "young fruit", including shell Some people chew areca nut for several hours, causing chemical stimulation and mechanical damage to oral mucosa, leading to submucous fibrosis, leukoplakia and mossy lesions, and further deterioration is oral cancer But the Chinese medicine areca is the decoction oral, will not stimulate the oral mucosa for a long time And dosage, course of treatment, use habits and other aspects are different According to relevant personnel of China Resources Sanjiu group, the prescription disclosed in the specification of Zhengtian pill contains the processed products of aconite Aconite is the root processing product of Aconitum of Ranunculaceae, and Aconitum is the mother root of Aconitum of Ranunculaceae The parts of aconite and Aconitum are different Therefore, the toxicity of aconitine alkaloids in aconite was greatly reduced after processing The lack of evaluation leads to the trust crisis of traditional Chinese medicine The safety problem of traditional Chinese medicine caused by the toxicity of traditional Chinese medicine is a common problem in the field of traditional Chinese medicine However, experts pointed out that at present, many traditional Chinese medicine varieties lack of rigorous clinical data support, leading to the frequent trust crisis of traditional Chinese medicine "The national new drug registration method requires four phases of clinical practice, and all drugs should be four phases of clinical practice after marketing, which is equivalent to routine re evaluation, but many manufacturers have not done it." Safety and efficiency first pointed out that according to the evaluation of China food and drug administration, the post market evaluation includes two aspects, one is safety, the other is effectiveness "Now, many people have put forward that these Chinese patent medicines are not safe, and no unsafe data has been found on the Internet But this is not convincing Enterprises must do experiments, and it is a large number of multi centers Only do large sample, multi center experiments, you take out the objective data, we all understand at a glance " Experts said that the attitude towards adverse drug reactions in the whole Chinese medicine industry has long been problematic "We found that many of the adverse reactions in the instructions of Western medicine were long and long, while the traditional Chinese medicine often marked" unclear " They are desperate to find, we are desperate to hide Ji Shaoliang said that for this difference, the industry should attach great importance to it Because as far as possible to find and fully explain adverse drug reactions, it is helpful for patients to use drugs safely Sun Xiaobo, deputy director of the Institute of medicinal plants, Chinese Academy of Medical Sciences, suggested that traditional Chinese medicine enterprises should learn from these recent events, further actively track the adverse reactions of products in the market and the announcements, complaints and research results of regulatory departments and relevant scientific research institutions, and truly release relevant information At the same time, strengthen the re evaluation after listing, and the third-party authority shall conduct relevant tests "These events suggest that when we develop new drugs, it is necessary to conduct" three causes "(teratogenesis, carcinogenesis, mutagenesis) test This should be an old problem in the industry for many years, and it is time to take action." Chen Keji, academician of the Chinese Academy of engineering and chief researcher of the Chinese Academy of traditional Chinese medicine, said that no matter from the national level or pharmaceutical enterprises, we should strengthen the post clinical research and evaluation of traditional Chinese medicine "Tracking the patients who have used traditional Chinese medicine to see how many years later the patients have used a certain kind of traditional Chinese medicine, which is very illustrative." The reason why traditional Chinese medicine enterprises are unable to pay for the R & D expenses is the lack of clinical data "When the price of medicines is reduced, so are the prices of Chinese patent medicines Recently, I heard that the prices of the exclusive varieties listed in the catalogue of basic medicines will be reduced." Zhang Dayong, deputy general manager of Sichuan xinhehua Yinpian Co., Ltd., told the economic reference newspaper that the government did not give much policy support to the traditional Chinese medicine enterprises and did not consider the R & D investment of the enterprises Instead, the continuous price reduction led to the reduction of the profits of the enterprises, and the enterprises could not afford to do other things According to the introduction, it takes about 1 billion yuan to make a comprehensive scientific evaluation of a traditional Chinese medicine Ordinary Chinese patent medicine enterprises simply can't afford such a high cost to conduct experiments Moreover, the evaluation of a certain medicinal material is very complex and takes a certain amount of time What's more, the evaluation is not protected by intellectual property rights "When a certain enterprise makes it, it will become a shared product of the society." Zhang Dayong said that the sales volume of 300 million yuan of ordinary Chinese patent medicines is very good, but it is impossible to give money for scientific evaluation Some experts suggest that the government and enterprises should jointly invest in the evaluation of the varieties of traditional Chinese medicine and study its mechanism and adverse reactions.